Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Trading 04-08 10:16:15 EDT

1.18

+0.03

+2.61%

High1.23	Low1.18	Vol163.06K
Open1.20	D1 Closing1.15	Amplitude4.35%
Mkt Cap137.19M	Tradable Cap118.94M	Total Shares116.26M
T/O196.24K	T/O Rate0.16%	Tradable Shares100.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":1.18,"timestamp":1775657772982,"preClose":1.15,"halted":0,"volume":163060,"delay":0,"changeRate":0.026086956521739157,"floatShares":100797117,"shares":116263459,"eps":-1.149999,"marketStatus":"Trading","change":0.03,"latestTime":"04-08 10:16:15 EDT","open":1.2,"high":1.23,"low":1.18,"amount":196243.085038,"amplitude":0.043478,"askPrice":1.19,"askSize":911,"bidPrice":1.18,"bidSize":1458,"shortable":3,"etf":0,"ttmEps":-1.149999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775678400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":1.15,"preHourTrading":{"tag":"盘前","latestPrice":1.21,"preClose":1.15,"latestTime":"09:19 EDT","volume":2047,"amount":2459.5288395,"timestamp":1775654350693,"change":0.06,"changeRate":0.052174,"amplitude":0.050783},"postHourTrading":{"tag":"盘后","latestPrice":1.1701,"preClose":1.15,"latestTime":"19:41 EDT","volume":185179,"amount":214289.6892,"timestamp":1775605260361,"change":0.0201,"changeRate":0.017478,"amplitude":0.109478},"volumeRatio":1.328843,"impliedVol":0.9972,"impliedVolPercentile":0.444},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"2624468236","title":"Fate Therapeutics grants 7,260 RSUs to newly hired employee under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624468236","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624468236?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:11","pubTimestamp":1775160669,"startTime":"0","endTime":"0","summary":"Fate Therapeutics granted restricted stock units covering 7,260 common shares to one newly hired non-executive employee on April 1, 2026.RSUs vest over four years, with 25% vesting on each anniversary of grant date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3s3zPS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","FATE","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4112","LU2095319765.USD","BK4588","BK4139","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624768232","title":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624768232","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624768232?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:05","pubTimestamp":1775160300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/02/3267832/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617566017","title":"Fate Therapeutics Grants 50,700 RSU Inducement Awards to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566017?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:06","pubTimestamp":1772658380,"startTime":"0","endTime":"0","summary":"Fate Therapeutics said it granted restricted stock units covering 50,700 shares to three newly hired non-executive employees. The awards were made under the company’s Amended and Restated Inducement Equity Plan and vest over four years, with 25% vesting on each anniversary of the March 2, 2026 grant date, subject to continued employment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL4fdR3q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","IE00B3QW5Z07.USD","FATE","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","BK4139","BK4112","SG9999014021.USD","LU2095319765.USD","SG9999014013.SGD","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569502","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569502","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569502?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:05","pubTimestamp":1772658300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March  04, 2026  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripoten","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249721/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616536575","title":"Bank of America Securities Sticks to Their Hold Rating for Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616536575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616536575?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:56","pubTimestamp":1772618176,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Hold rating on Fate Therapeutics, with a price target of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-hold-rating-for-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-hold-rating-for-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616371248","title":"Fate Therapeutics to Join Leerink Partners 2026 Global Healthcare Conference Fireside Chat and Investor Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2616371248","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616371248?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:06","pubTimestamp":1772571971,"startTime":"0","endTime":"0","summary":"Fate Therapeutics to Join Leerink Partners 2026 Global Healthcare Conference Fireside Chat and Investor Meetings               Fate Therapeutics Inc. will participate in a fireside chat and host inves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL51BxjT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4207","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","NDAQ","SG9999014021.USD","IE00BKPKM429.USD","BK4585","SG9999014039.USD","FATE","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4112","MNSH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616325661","title":"ROC Strengthens Position as Leading Age Estimation Provider in NIST’s Child Online Safety Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2616325661","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616325661?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:30","pubTimestamp":1772544600,"startTime":"0","endTime":"0","summary":"ROC’s algorithmic strength secures NIST’s top ranking in age estimation accuracy; ranked #1 globally in Child Online Safety and Mugshot dataset, underscoring ROC’s commitment to developing digital saf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/03/3248366/0/en/ROC-Strengthens-Position-as-Leading-Age-Estimation-Provider-in-NIST-s-Child-Online-Safety-Evaluation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROC","FATE","BK4023","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616342588","title":"Fate Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342588?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:59","pubTimestamp":1772539181,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryFate Therapeutics Inc FATE.OQ reported a quarterly adjusted loss of 27 cents per share for the quarter ended D","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL8N3ZR193:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614040673","title":"Fate Therapeutics reports lower Q4 collaboration revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2614040673","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614040673?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:09","pubTimestamp":1772114954,"startTime":"0","endTime":"0","summary":"Fate Therapeutics reports lower Q4 collaboration revenueOverviewBiopharmaceutical firm's Q4 collaboration revenue fell yr/yrCompany reported Q4 net loss of $32.4 mlnOperating expenses decreased 30% in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM0S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614040399","title":"Fate Therapeutics posts FY 2025 net loss of USD 136.3 million, down 26.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614040399","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614040399?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:02","pubTimestamp":1772114541,"startTime":"0","endTime":"0","summary":"Fate Therapeutics posts FY 2025 net loss of USD 136.3 million, down 26.8%               Fate Therapeutics reported Q4 2025 revenue of USD 1.4 million and a net loss of USD 32.4 million, with total ope","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL2KNGtm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014013.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4112","SG9999014005.SGD","SG9999014021.USD","FATE","LU2095319765.USD","BK4588","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614040590","title":"Fate Therapeutics Inc: Projected Operating Runway Through Year-End 2027, Supported by $205 Mln in Cash, Cash Equivalents, and Investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2614040590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614040590?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:00","pubTimestamp":1772114410,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA7T8HHP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614834040","title":"Fate Therapeutics Q4 Basic EPS USD -0.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2614834040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614834040?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:00","pubTimestamp":1772114402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX807451:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614408390","title":"Fate Therapeutics Q4 Income From Operations USD -34.721 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614408390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614408390?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:00","pubTimestamp":1772114402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX807451:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614028936","title":"Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2614028936","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614028936?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:00","pubTimestamp":1772114400,"startTime":"0","endTime":"0","summary":"Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis pat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245685/24675/en/Fate-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2108987350.USD","LU0096364046.USD","LU0175139822.USD","BK4022","LU1732799900.SGD","LU0006306889.USD","LU1116320901.HKD","LU1988902786.USD","LU2237443895.HKD","BK4213","LU0265550359.USD","IE00B19Z4B17.USD","BK4080","LU1064131342.USD","LU1732800096.USD","LU0266512127.USD","LU0795875169.SGD","LU0963586101.USD","LU1032955483.USD","SG9999015358.SGD","BK4109","LU2237443549.SGD","IE00BVYPNW00.USD","LU0061474960.USD","BK4177","LU0289960550.SGD","LU0949170772.SGD","LU0456854461.SGD","LU1894683348.USD","LU1868837300.USD","LU1894683264.USD","IE00BBT3K403.USD","LU0225283273.USD","LU0661504455.SGD","LU0265550946.USD","LU1162221912.USD","BK4139","BK4006","LU1670710661.SGD","LU0823417653.USD","LU2506951958.HKD","LU0795875086.SGD","SG9999004303.SGD","SG9999002232.USD","IE00BGHQF631.EUR","LU2264538146.SGD","BK4231","LU1003077747.HKD","LU0823417737.USD","LU2463526074.USD","LU0106261372.USD","LU0545039389.USD","LU2125154935.USD","LU0323591593.USD","BK4610","LU0061475181.USD","SG9999014575.USD","IE0031619046.USD","LU2065731478.USD","LU1868836591.USD","BK4187","BK4077","IE00BDGV0183.EUR","IE00BLSP4239.USD","SG9999015341.SGD","BK4230","LU2237443465.HKD","LU2347655156.SGD","LU2506952170.USD","LU2237443978.SGD","LU0868494617.USD","LU1116320737.USD","IE00B66KJ199.SGD","BK4581","BK4534","IE00B7SZL793.SGD","LU0553294199.USD","LU1221951129.SGD","SG9999014559.SGD","LU1670711123.USD","BK4500","SG9999003800.SGD","LU2237957811.SGD","BK4533","LU2097829019.USD","LU0098860793.USD","BK4588","IE00BVYPNV92.GBP","LU2237443622.USD","LU1221951046.USD","IE00B42XCP33.USD","FATE","LU2237957902.USD","LU1196500208.SGD","SG9999014567.USD","LU2279689827.SGD","LU0950375773.USD","LU1815333072.USD","BK4585","LU1059921491.USD","BK4504","IE00B3PB1722.GBP","LU0912757837.SGD","LU2125154778.USD","LU2506951875.HKD","LU0234572021.USD","LU1718418525.SGD","IE00BLSP4452.SGD","BK4532","LU0957791311.USD","SGXZ23171101.USD","BK4559","LU1670711040.USD","LU0320765646.SGD","LU1670710588.SGD","LU2360032135.SGD","LU1868837136.USD","SG9999014542.SGD","IE00BN8TJ469.HKD","LU1868836757.USD","LU2133065610.SGD","BK4008","LU1868836914.USD","SG9999011175.SGD","SG9999002224.SGD","LU1032466523.USD","LU2506952097.USD","LU0738911758.USD","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612445027","title":"Aware Raises the Bar with Industry-Leading Biometric Certifications and Evaluations","url":"https://stock-news.laohu8.com/highlight/detail?id=2612445027","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612445027?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:31","pubTimestamp":1771335060,"startTime":"0","endTime":"0","summary":"Third-party evaluations validate fraud-resilient, low-friction identity verification as deepfakes and injection attacks accelerate.BURLINGTON, Mass., Feb.  17, 2026  (GLOBE NEWSWIRE) -- As generative ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239309/0/en/Aware-Raises-the-Bar-with-Industry-Leading-Biometric-Certifications-and-Evaluations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AWRE","BK4139","FATE","BK4023","DHS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608800117","title":"Fate Therapeutics Grants Stock Options and RSUs to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2608800117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608800117?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:05","pubTimestamp":1770152714,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc. has granted a newly hired non-executive employee non-qualified stock options to purchase 120,000 shares of common stock at an exercise price of $1.19 per share, the company’s closing price on January 30, 2026. Additionally, the employee received restricted stock units  representing 90,000 shares. The stock options will vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the next three years. The RSUs will vest in equal 25% increments on each anniversary of the grant date over four years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this new","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLr02VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","SG9999014005.SGD","LU2095319765.USD","LU2210150020.SGD","BK4585","SG9999014021.USD","NDAQ","IE00BGHQF748.EUR","BK4112","FATE","SG9999014039.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4139","LU2210149790.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608266800","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608266800","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608266800?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:05","pubTimestamp":1770152700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  03, 2026  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3231595/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604408499","title":"Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year","url":"https://stock-news.laohu8.com/highlight/detail?id=2604408499","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604408499?lang=en_us&edition=fundamental","pubTime":"2026-01-17 20:45","pubTimestamp":1768653917,"startTime":"0","endTime":"0","summary":"Key Insights Significantly high institutional ownership implies Fate Therapeutics' stock price is sensitive to their...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fate/fate-therapeutics/news/great-week-for-fate-therapeutics-inc-nasdaqfate-institutiona-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fate/fate-therapeutics/news/great-week-for-fate-therapeutics-inc-nasdaqfate-institutiona-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQY","TQQQ","GPIQ","FATE","MNQmain","QID","QQQE","QYLD","TSYW.SI","QYLG","USAW.SI","QQQJ","NQmain","PSQ","USJW.SI",".IXIC","BK4139","NVIW.SI","SQQQ","QQQM","QLD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2603575913","title":"Top Fate Therapeutics Insider Makes a Quiet Move That Investors Can’t Ignore","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603575913?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:01","pubTimestamp":1768269691,"startTime":"0","endTime":"0","summary":"New insider activity at Fate Therapeutics ( ($FATE) ) has taken place on January 12, 2026. Chief Legal and Compliance Officer Cindy Tahl has recent...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-fate-therapeutics-insider-makes-a-quiet-move-that-investors-cant-ignore-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-fate-therapeutics-insider-makes-a-quiet-move-that-investors-cant-ignore-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139","BK4211","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601378588","title":"Fate Therapeutics Grants Stock Options and RSUs to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2601378588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601378588?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:05","pubTimestamp":1767647123,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc. has granted non-qualified stock options to one newly hired non-executive employee for the purchase of 48,000 shares at an exercise price of $0.98 per share, reflecting the closing price on December 31, 2025. Additionally, restricted stock units  totaling 79,400 shares were awarded to four newly hired non-executive employees. The stock options vest over four years, with 25% vesting after one year and the remainder vesting in equal monthly installments over the following three years. The RSUs also vest over four years, with 25% vesting on each anniversary of the grant date. Vesting is contingent on continued employment with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL2MFqVb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","NDAQ","BK4112","SG9999014021.USD","LU0314104364.USD","BK4588","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","BK4585","FATE","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0417},{"period":"1month","weight":-0.1353},{"period":"3month","weight":0.036},{"period":"6month","weight":-0.2857},{"period":"1year","weight":0.2646},{"period":"ytd","weight":0.1704}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0178},{"period":"1year","weight":0.307},{"period":"ytd","weight":-0.0333}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.538462,"avgChangeRate":-0.002272},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.020051},{"month":6,"riseRate":0.5,"avgChangeRate":0.003206},{"month":7,"riseRate":0.416667,"avgChangeRate":0.050198},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.024603},{"month":9,"riseRate":0.416667,"avgChangeRate":0.00072},{"month":10,"riseRate":0.25,"avgChangeRate":-0.091603},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction